viewCB2 Insights Inc.

CB2 Insights to take over clinical cannabis care at six New Jersey facilities

The company is acquiring the assets of New Jersey Alternative Medicine

Cannabis leaf and stethoscope
New Jersey marks the third US state CB2 has expanded into since April

CB2 Insights (CSE:CBII) (OTCMKTS:CBIIF) bolstered its clinical division Tuesday by taking over the assets of New Jersey Alternative Medicine.

The Toronto-based company will assume all clinical care of the 15,000 patients at NJAM’s 6 facilities in the state. The clinics are part of the Canna Care Docs brand, which is the largest multi-state medical cannabis clinic operator in the US.

New Jersey marks the third US state CB2 has expanded into since April, following the acquisitions of Relaxed Clarity and MedEval Clinics in Colorado and Arizona. All told, the company will operate about 40 medical cannabis evaluation and education facilities in the US, in addition to telemedicine services to patients in Maine and New York.

The company's share price rose nearly 3% to C$0.18 in Toronto and 5.7% to US$0.14 on OTC Markets.

READ: CB2 Insights strengthens board with new member and appoints chairman

“New Jersey is an exciting market for CB2; with over 50,000 active patients and growing across the state, and further advancements to the medical cannabis program to expand on indications and patient access,” CEO Prad Sekar said. “NJAM, who has already captured care of more than 25% of the market, will provide CB2 with a solid base of patients and revenue to capitalize on the growth this state will continue to see.”

CB2 Insights is a data-driven company with the aim of folding cannabis treatment into the traditional health care sector by collecting information and offering predictive point-of-care analysis.

Growth plans

In a separate note to shareholders Tuesday, CEO Prad Sekar updated the investment community on the company's corporate strategy.

“We continue our move to become the leading independent provider of clinical research and the industry’s premier data insights platform for clinically-led Real World Evidence studies,” said Sekar.

“Today pharmaceutical and phytopharmaceutical companies spend hundreds of millions of dollars on clinical trials and data to support their R&D and product commercialization efforts.  We believe we are very well positioned to be a valuable and trusted source of data to support these efforts. We have been fortunate and appreciate the support of some of the largest institutional investors in the cannabis industry who are allowing us to grow aggressively and scale our business to profitability.”

CB2's annual general meeting will be held this week in Mississauga, Ontario.

--Updates with additional comment--

--Addiftional reporting by Angela Harmatas--

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: CB2 Insights Inc.

Price: - -

Market: CSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...


Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read